移到主要內容

長庚大學
:::
林俊彥教授_照片

林俊彥 教授兼院長 / Chun-Yen Lin M.D. Ph.D.

職稱： 院長/教授

現職： 長庚大學醫學院

信箱： chunyenlin@cgmh.org.tw

電話： 03-2118800 #5168

學歷： 英國牛津大學博士

專長領域： 癌症免疫

經歷

2017-2023  長庚紀念醫院內科部 主任
2016-2017  長庚紀念醫院內科部 副主任
2016-2017  長庚紀念醫院醫學研究部 副主席
2014-2016  長庚紀念醫院肝臟科 主任
2012-2016  長庚紀念醫院醫學教育委員會 副主席
2011-2015  長庚大學醫學院 副主任

學歷

2002  英國牛津大學 免疫學 博士
1987  台北醫學大學 醫學系 醫學士

研究方向

病毒性肝炎、肝硬化和肝癌之臨床與轉化研究

研究論文(選錄)

  • Huang CH, Tsai MH, Lin CY*. Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis. J Hepatol. 2024 Aug;81(2):e69-e70.
  • Lin PT, Hsu YC, Kao YT, Teng W, Hsieh YC, Chen WT, Su CW, Wang CT, Chai PM, Lin CC, Lin CY*, Lin SM. Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor. Am J Cancer Res. 2024 Mar 15;14(3):1306-1315.
  • Su CW, Teng W, Lin PT, Wu TH, Hsu YC, Hsieh YC, Huang CH, Chen WT, Lin CC, Lin CY*, Lin SM. A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefit. Am J Cancer Res. 2023 Nov 15;13(11):5482-5492.
  • Teng W, Cheng TA, Lin PT, Lin CC, Lin CY*, Lin SM. Combination of systemic immune-inflammation index and albumin-bilirubin grade predict prognosis of regorafenib in unresectable hepatocellular carcinoma. Am J Cancer Res. 2023 Jun 15;13(6):2702-2713.
  • Lin YC, Wu CH, Chen PJ, Huang CH, Yang CK, Dutta A, Huang CT, Lin CY*. Murine cytotoxic CD4+ T cells in the tumor microenvironment are at a hyper-maturation stage of Th1 CD4+ T cells sustained by IL-12. Int Immunol. 2023 Aug 7;35(8):387-400.
  • Lin JC, Pan KL, Li CF, Lee KF, Lin KY, Lin KM, Lin CY*. Altered subgroups of regulatory T cells in patients with primary Sjögren's syndrome. Heliyon. 2023 Apr 18;9(5):e15565.
  • Su CW, Teng W, Lin PT, Jeng WJ, Chen KA, Hsieh YC, Chen WT, Ho MM, Hsieh CH, Wang CT, Chai PM, Lin CC, Lin CY*, Lin SM. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. Cancer Med. 2023 Mar;12(6):7077-7089.
  • Teng W, Lin CC, Su CW, Lin PT, Hsieh YC, Chen WT, Ho MM, Wang CT, Chai PM, Hsieh JC, Lin CY*, Lin SM. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. Am J Cancer Res. 2022 Apr 15;12(4):1899-1911.
  • Teng W, Jeng WJ, Chen WT, Lin CC, Lin CY*, Lin SM, Sheen IS. Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients. Cancer Med. 2022 Oct;11(20):3786-3795.
  • Huang CH, Fan JH, Jeng WJ, Chang ST, Yang CK, Teng W, Wu TH, Hsieh YC, Chen WT, Chen YC, Sheen IS, Lin YC, Lin CY*. Innate-like bystander-activated CD38+ HLA-DR+ CD8+ T cells play a pathogenic role in patients with chronic hepatitis C. Hepatology. 2022 Sep;76(3):803-818.
  • Lin PT, Teng W, Jeng WJ, Chen WT, Hsieh YC, Huang CH, Lui KW, Hung CF, Wang CT, Chai PM, Lin CC, Lin CY*, Lin SM, Sheen IS. Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization. Diagnostics (Basel). 2022 Mar 9;12(3):665.
  • Lin CY*, Chien RN, Sheen IS. The 2020 Nobel Prize in medicine for the discovery of hepatitis C virus: An epic saga of the fight against a troublesome virus. Biomed J. 2021 Oct;44(5):567-569.
  • Lin PT, Teng W, Jeng WJ, Lin CY*. Reply to letter to the editor: The incidence and predictors of post transarterial chemoembolization variceal bleeding in hepatocellular carcinoma patients. J Formos Med Assoc. 2021 Jan;120(1 Pt 3):785-786.
  • Hsu CY, Lin YC, Chang LY, Huang SK, Huang CH, Yang CK, Huang CT, Lin CY*. Therapeutic Role of Inducible Nitric Oxide Synthase Expressing Myeloid-Derived Suppressor Cells in Acetaminophen-Induced Murine Liver Failure. Front Immunol. 2020 Oct 29;11:574839.
  • Liu YC, Jeng WJ, Cheng YT, Hsieh YC, Teng W, Chen YC, Lin CY*, Chien RN, Sheen IS. Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients. Medicine (Baltimore). 2020 Sep 11;99(37):e21898.